MIT Sloan logo MIT logo

Research


Just how good an investment is the biopharmaceutical sector?

2017
Nature Biotechnology
Richard T Thakor, Nicholas Anaya, Yuwei Zhang, Christian Vilanilam, Kien Wei Siah, Chi Heem Wong

Re-inventing drug development: A case study of the I-SPY 2 breast cancer clinical trials program

2017
Contemporary Clinical Trials 62 (2017) 168–174
Sonya Das

Accelerating Biomedical Innovation: A Case Study of the SPARK Program at Stanford University, School of Medicine

2017
Drug Discovery Today 22:7 (2017)
Esther S. Kim, Paige M.C. Omura

Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology

2017
JAMA Oncology (2017)
Vahid Montazerhodjat; Shomesh E. Chaudhuri; Daniel J. Sargent

New directions for the FDA in the 21st century

2017

Letter to Senators Wyden and Grassley: comment on their Sovaldi report

2016

Buying Cures vs. Renting Health: Financing Healthcare via Consumer Loans

2016
Science Translational Medicine 8(2016), 327ps6
Vahid Montazerhodjat and David Weinstock

Health, Wealth, and the 21st Century Cures Act

2016
JAMA Oncology 2(2016), 17–18.
Tomas Philipson and Andrew von Eschenbach

Price, Value, and the Cost of Cancer Drugs

2016
Lancet Oncology 17(2016), 3–5.
Tito Fojo  

Business Models to Cure Rare Disease: A Case Study of Solid Biosciences

2016
Journal of Investment Management 14(2016), 87–101.
Esther Kim

© 2020 Andrew W. Lo, MIT Sloan School of Management. All rights reserved.